{
    "clinical_study": {
        "@rank": "75353", 
        "arm_group": {
            "arm_group_label": "Test Drug", 
            "arm_group_type": "Experimental", 
            "description": "recombinant human \u03b1-galactosidase A"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and exploratory efficacy of GC1119\n      (recombinant human \u03b1-galactosidase A) for enzyme replacement therapy in Fabry disease\n      patients."
        }, 
        "brief_title": "Evaluate the Safety and Exploratory Efficacy of GC1119", 
        "condition": "Fabry Disease", 
        "condition_browse": {
            "mesh_term": "Fabry Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with a current diagnosis of Fabry's disease\n\n          -  Plasma \u03b1-gal activity of \u2264 1.5mnol/hr/ml and have a mutation in \u03b1-galactosidase A\n             gene\n\n          -  Males \u2265 16 years old\n\n          -  Subjects capable of performing this clinical trial in an appropriate manner\n\n          -  Informed consent form voluntarily signed by the subject(or his legally acceptable\n             representative if the subject is under 20 years old) to participation in the study\n\n          -  Agreement to contraception during the study period\n\n        Exclusion Criteria:\n\n          -  Serum creatinine > 2.5mg/dl\n\n          -  Subjects have a plan to kidney transplantation\n\n          -  Subjects have undergone kidney transplantation\n\n          -  Subjects are currently on dialysis\n\n          -  Subjects have a clinically significant organic disease(cardiovascular, hepatic,\n             pulmonary, neurologic, or renal disease)that in the opinion of the investigator would\n             preclude participation in the trial\n\n          -  Known life-threatening hypersensitivity(anaphylactic reaction) to \u03b1-galactosidase\n\n          -  Treatment with another investigational product within 30days from the administration\n             of study drug dosing or plans to be treated with another investigational product\n             during the study period\n\n          -  Known hypersensitivity to any of the ingredients of study drug(including excipients)\n\n          -  Subjects need the medication of prohibited drug\n\n          -  Alcoholism or drug addiction"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653444", 
            "org_study_id": "GC1119_P1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Test Drug", 
                "description": "biweekly, 0.5mg/kg IV infusion", 
                "intervention_name": "GC1119, 0.5mg/kg", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Test Drug", 
                "description": "biweekly, 1.0mg/kg IV infusion", 
                "intervention_name": "GC1119, 1.0mg/kg", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 30, 2012", 
        "location": [
            {
                "contact": {
                    "email": "hwyoo@amc.seoul.kr", 
                    "last_name": "Han Wook Yoo, M.D., Ph.D.", 
                    "phone": "82-2-3010-3374"
                }, 
                "facility": {
                    "address": {
                        "city": "Songpa-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "investigator": {
                    "last_name": "Han Wook Yoo, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ldh@schmc.ac.kr", 
                    "last_name": "Dong Hwan Lee, M.D., Ph.D.", 
                    "phone": "82-2-709-9341"
                }, 
                "facility": {
                    "address": {
                        "city": "Yongsan-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul"
                    }, 
                    "name": "Soon Cung Hyang University Hospital"
                }, 
                "investigator": {
                    "last_name": "Dong Hwan Lee, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ybsohn@ajou.ac.kr", 
                    "last_name": "Young Bae Sohn, M.D.", 
                    "phone": "82-31-219-4447"
                }, 
                "facility": {
                    "address": {
                        "city": "Yeongtong-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Suwon"
                    }, 
                    "name": "Ajou University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Young Bae Sohn, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Multicenter and Dose Escalation Phase 1 Study to Evaluate the Safety and Exploratory Efficacy of GC1119(Recombinant Human \u03b1-galactosidase A) for Enzyme Replacement Therapy in Fabry Disease Patients", 
        "overall_contact": {
            "email": "hwyoo@amc.seoul.kr", 
            "last_name": "Han Wook Yoo, M.D., Ph.D.", 
            "phone": "82-2-3010-3374"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "10weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653444"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "change and %change of Plasma GL-3 concentration", 
                "safety_issue": "No", 
                "time_frame": "baseline and 10weeks"
            }, 
            {
                "measure": "The ratio of subjects whose plasma GL-3 values are within reference range", 
                "safety_issue": "No", 
                "time_frame": "10weeks"
            }, 
            {
                "measure": "change and %change of urine GL-3 concentration", 
                "safety_issue": "No", 
                "time_frame": "baseline and 10weeks"
            }, 
            {
                "measure": "change and %change of kidney function", 
                "safety_issue": "No", 
                "time_frame": "baseline and 10weeks"
            }, 
            {
                "measure": "change and %change of kidney size", 
                "safety_issue": "No", 
                "time_frame": "baseline and 10weeks"
            }, 
            {
                "measure": "change and %change of heart size", 
                "safety_issue": "No", 
                "time_frame": "baseline and 10weeks"
            }, 
            {
                "measure": "change of results of cornial opacity examination", 
                "safety_issue": "No", 
                "time_frame": "baseline and 10weeks"
            }, 
            {
                "measure": "change of scores that are measured by pain questionnaire", 
                "safety_issue": "No", 
                "time_frame": "baseline and 10weeks"
            }
        ], 
        "source": "Green Cross Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Green Cross Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2012"
    }
}